ROI in Pharmaceutical R&D: How to Halt the Decline

Jan 2020| PHM218A| BCC Publishing

Report Highlights

The global orphan drugs market should reach $315.6 billion by 2024 from $127.5 billion in 2017 at a compound annual growth rate (CAGR) of 13.8% for the forecast period of 2017 to 2024.

Report Includes

  • 49 data tables and 30 additional tables
  • An assessment of return on investment (ROI) in R&D by top pharmaceutical companies within the industry
  • Analyses of the global market trends for various chronic disease areas, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2024
  • Pipeline analysis of various therapeutic drugs with oncology being the largest, and coverage of ongoing clinical trials and promising forthcoming therapies in late stage etc.
  • Outlining details of many factors involved in calculating ROI in R&D in pharma and how some of those factors are adjusted/developed to improve R&D ROI
  • Discussion of the competitive landscape and key mergers and acquisition deals, partnerships, collaborations during the timeframe, 2014-2024
  • Profile descriptions of top 15 pharmaceutical companies, their sales data, market capitalization and areas of R&D etc., including 23andMe, AstraZeneca PLC, Celgene Corp., Eli Lilly and Co., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc. and Sanofi

Report Scope

The scope of this study begins with the challenges facing biotech and pharmaceutical companies today. It goes on to discuss regulatory approval processes in various countries, how these are changing, and the knock-on effects which the pharma/biotech companies will have to address. The report then reviews several key financial ratios, then discusses how to maximize clinical development success rate. We then go into how machine learning (ML) and artificial intelligence (AI), along with Big Data, are disrupting the pharma/biotech industry, in a positive way. The report then reviews the global markets for treatments for selected cancers, chronic diseases, cardiovascular disease, neurological diseases, infectious diseases and rare diseases. Chapter 15 discusses how companies need to deeply integrate ML, AI and Big Data into drug discovery and clinical testing—or risk falling behind the competition. The report wraps up with summaries of selected companies active in these spaces and beginning to utilize digital tools in R&D.

Analyst Credentials

Valerie Kellogg, RRT, BA, MS/MBA is an experienced medical device and pharmaceutical professional with international market research experience. She has authored numerous reports on topics ranging from the treatment of obesity to ablation devices, from wound care to the treatment of chronic migraine. Her strong focus areas include oncology, treatment of chronic disease, the latest in surgical devices and analysis of potential acquisitions.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Title/Chapter Name Pages Price Member Price
Full Report: ROI in Pharmaceutical R&D: How to Halt the Decline 196 $5,500 Free
Chapter- 1: Introduction3Free DownloadFree
Chapter- 2: Summary10$250Free
Chapter- 3: Challenges Facing Pharma and Biotech Companies21$592Free
Chapter- 4: Regulatory Overview and New Drug Approvals11$310Free
Chapter- 5: Key Financial Ratios for Pharma and Biotech Companies4$113Free
Chapter- 6: Maximizing Clinical Development Success Rates13$367Free
Chapter- 7: The Advantages of Being—or Acting—Small3$85Free
Chapter- 8: The Digital Transformation of Biopharma Companies14$395Free
Chapter- 9: Leveraging Open Innovation to Solve Development Challenges5$141Free
Chapter- 10: The Global Pharma and Biotech Market for Oncology14$395Free
Chapter- 11: The Global Pharma and Biotech Market for Chronic Diseases6$169Free
Chapter- 12: The Global Pharma and Biotech Market for Cardiovascular Disease4$113Free
Chapter- 13: The Global Pharma and Biotech Market for Neurological Diseases5$141Free
Chapter- 14: The Global Pharma and Biotech Market for Infectious Diseases14$395Free
Chapter- 15: The Global Pharma and Biotech Market for Rare Diseases7$197Free
Chapter- 16: The Changing Future of Biopharma Work2$56Free
Chapter- 17: Company Profiles59$1,664Free
Chapter- 18: Appendix: Acronyms1$28Free
Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report